Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ceftazidime in septicaemia.

P Lundbergh, C Jarstrand, L Morfeldt-Månson

    The Journal of Antimicrobial Chemotherapy
    |July 1, 1983
    PubMed
    Summary

    Ceftazidime effectively treated Gram-negative septicaemia and bacteraemia in elderly patients. Monitoring serum concentrations is crucial for patients with impaired renal function to ensure optimal dosing.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden.

    European journal of clinical pharmacology·2018
    Same author

    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virological response in chronic hepatitis C.

    Journal of viral hepatitis·2018
    Same author

    Activated Cellular Immunity in Chronic Hepatitis C.

    Hematology (Amsterdam, Netherlands)·2016
    Same author

    Incidence and outcome of Staphylococcus aureus endocarditis--a 10-year single-centre northern European experience.

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015
    Same author

    Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

    Alimentary pharmacology & therapeutics·2015
    Same author

    Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.

    Journal of viral hepatitis·2013

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Nephrology

    Background:

    • Septicaemia and bacteraemia pose significant health risks, particularly in elderly populations.
    • Gram-negative bacteria are common causative agents of bloodstream infections.
    • Ceftazidime is a third-generation cephalosporin antibiotic with broad-spectrum activity.

    Purpose of the Study:

    • To evaluate the efficacy and safety of ceftazidime in treating septicaemia and bacteraemia.
    • To assess ceftazidime pharmacokinetics in patients with renal impairment.
    • To determine optimal dosing strategies for ceftazidime in this patient cohort.

    Main Methods:

    • Retrospective analysis of 35 patients with 37 episodes of septicaemia or bacteraemia.
    • Treatment with ceftazidime (1-2 g twice daily) for 3-17 days.
    • Pharmacokinetic profiling of serum concentrations in 12 patients with renal dysfunction.

    Main Results:

    • An 81% cure rate was observed in patients treated with ceftazidime.
    • Escherichia coli was the most frequent pathogen identified.
    • Antibiotic sensitivity testing revealed high susceptibility to ceftazidime among tested strains.
    • Dose adjustments were necessary in some patients with renal impairment based on serum concentrations.

    Conclusions:

    • Ceftazidime demonstrates significant success in treating Gram-negative septicaemia.
    • Careful monitoring of serum concentrations and dose adjustment are recommended for patients with decreased renal function.
    • Further research into individualized dosing may optimize ceftazidime therapy.

    Related Experiment Videos